WIPRO
10.3.2021 15:32:07 CET | Business Wire | Pressemeddelelse
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), en førende global virksomhed inden for informationsteknologi, konsulentvirksomhed og forretningsprocesser annoncerede i dag udnævnelsen af Pierre Bruno som administrerende direktør, Europa.
I denne rolle vil Bruno lede Wipro’s forretning i seks forskellige regioner på tværs af Europa. Denne udnævnelse, er en dristig indikation af virksomhedens fortsatte investering og fokus på det europæiske marked, som bygger på Wipros fremdrift i hele regionen i de seneste år.
“Pierre har mere end 25 års erfaring inden for IT-infrastruktur, konsulent og servicesektoren. Han har leder virksomheder i både hypervækstmiljøer og inden for teknologi transformation. Med hans erfaring i ledelse af store teams er han godt positioneret til at føre Wipros vækstrejse videre i Europa,” sagde Thierry Delaporte, CEO & MD, Wipro Limited.
“Jeg er begejstret for muligheden for at lede Wipro’s aktiviteter på det europæiske marked, der byder på fantastiske muligheder for vækst. Jeg ser frem til at videreudvikle samt fremme vores engagement over for vores europæiske kunder, når de navigerer i deres forretningstransformation og fortsætter med at udvikle sig i en digital verden,” sagde Pierre Bruno , Administrerende direktør, Europa .
Bruno kommer til Wipro fra DXC Technology, hvor han var vicepræsident og administrerende direktør for Sydeuropa, ansvarlig for alle dele af forretningen, herunder rådgivning, integration, apps, cloud og cybersikkerhed. Bruno arbejdede også for Dell i 14 år i flere roller i Asien, Stillehavsområdet, Japan og EMEA. Han spillede en central rolle i Dells transformation fra at sælge hardware til at blive en vigtig aktør inden for levering af infrastrukturløsninger.
Bruno har en kandidatgrad i forretningsadministration (MBA) med hovedfag i Marketing og økonometri fra HEC Graduate School i Paris. Han har også en kandidatgrad i bioteknik.
Wipro’s forpligtelse i Europa
Wipro’s europæiske tilstedeværelse omfatter seks regioner, bestående af Storbritannien og Irland, Tyskland, Schweiz, Norden, Benelux og Sydeuropa, samt tre near-shore leverancecentre og omfatter en bred vifte af betydelige kunder på tværs af brancher, hvoraf mange bliver supporteret af Wipro på deres teknologiste vækst samt transformationsrejse..
Nogle af de seneste aftaler i Europa omfatter
- En vigtig strategisk digital og IT-partnerskabsaftale med METRO AG, en førende global grossistvirksomhed.
- Et engagement med den Finland-baserede producent af ren energi Fortum for at hjælpe med at opgradere applikationslandskabet samt tilhørende serviceintegration,.
- En flerårig global aftale om automotive engineering services med den italienske bilgigant Marelli.
- I Tyskland arbejder vi sammen med Telefónica Germany/O2 og dets bredere økosystem til at transformere deres forretningssupportsystemer og tilhørende kvalitetssikring for at sikre en optimal kundeoplevelse og vækst i B2B-markedssegmentet.
- En strategisk, flerårig infrastruktur’s modernisering og digital transformations services fra det tyskbaserede energiselskab E.ON.
Om Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) er en førende global virksomhed inden for informationsteknologi, rådgivning og forretningsprocesser. Vi udnytter styrken af kognitive computing, hyper-automatisering, robotteknologi, cloud , analytics og nye teknologier til at hjælpe vores kunder med at tilpasse sig den digitale verden og gøre successfulde. En virksomhed, der er anerkendt globalt for sin omfattende portefølje af services, stærkt engagement i bæredygtighed samt virksomhedsetik , vi har over 190.000 dedikerede medarbejdere, der betjener vores kunder på seks kontinenter. Sammen kommer vi med nye ideer samt udvikler og skaber en bedre og dristig ny fremtid.
Forward-Looking Statements
The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers’ ability or willingness to purchase our offerings, delay prospective customers’ purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov
. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210310005602/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum